OBJECTIVE	The purpose of this prospective , open , randomized , controlled study was to investigate whether atorvastatin ( 10 mg/day ) would alter cardiovascular endpoints and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 ( creatinine clearance < 30 ml/min ) .\